EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Sol Gel Technologies Ltd (SLGL) fair value: what the stock is really worth

As of Sep 25, 2026: fair value of Sol Gel Technologies Ltd $8.28, price $66.85, upside -87.6%, quality 65 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · US · Home Israel · ISIN IL0011417206

SG Sol Gel Technologies Ltd logo Thin data Sep 27, 2026

Sol Gel Technologies Ltd

SLGL · US

Structural break: The valuation model sees a lasting decline in earnings power for this stock, the confidence band is broken. Treat the target with caution.

Stretched ValuationStrong overvaluation with only moderate quality.

!Fair value $8.28 · Strongly overvalued (−87.6%)
✓Quality 65/100
!Mixed Growth (revenue 3y +70.9 %/yr)
!Loss-making · -31.6% net margin (FY2025)
✓generates free cash flow
!Trails peers (1/8)
!Narrow moat 8/100
!Evidence only low, so the estimate is less certain
Watch Sol Gel Technologies Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$132.60 $3.66 Fair Value $8.28 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.

How to read this chart

60‑month range $3.66 – $132.60 · fair‑value band $6.42 – $8.96 · the $66.85 price screens above the $8.28 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.

Follow Sol Gel Technologies in your weekly email

Every Wednesday you see whether Sol Gel Technologies is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally.

Show more

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Stock analysis

Sol Gel Technologies Ltd (SLGL) currently trades at $66.85, while our model-based Fair Value estimate is $8.28, implying the stock looks roughly 707.1% overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of $8.46 per share, and 0 of the 7 models we run sit above the $66.85 price.

Bear case: the Multiples group reads lowest at $4.46, and 7 of the 7 models stay below the price. Evidence for this calculation is low.

Scenario range: $6.42 (bear) to $8.96 (bull), the price of $66.85 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 65/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Sol Gel Technologies Ltd reported revenue of $19.4M in FY2025 versus $31.3M in FY2021, a compound −11.3%/yr. Reported net income was −$6.1M in FY2025.

Key figures

Market cap $190M · EPS (TTM) $−5.62 · Net margin −31.6% · Return on equity −40.9% · Return on assets (EBIT) −30.8% · Operating margin −704% · Revenue growth (YoY) −96.6% · EPS growth (YoY) +488%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).

What moves the price

The share trades about 32% below its 52-week high and 139% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −88%, SLGL screens richer than that median.

Fair Value models

Bear $6.42 Fair Value $8.28 Bull $8.96
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF $8.14 $10.06 $15.66 74
Growth DCF $7.84 $10.59 $14.88 72
5Y Revenue Exit $5.59 $6.42 $8.10 67
All 7 models by family
DCF Models
FCF DCF $8.14 $10.06 $15.66 74
5Y Revenue Exit $5.59 $6.42 $8.10 67
10Y Revenue Exit $6.51 $8.46 $9.18 62
Multiples
EV/Revenue $4.13 $4.46 $4.79 52
Asset-Based
NCAV (Graham) $3.48 $4.67 $6.97 51
Growth DCF
Growth DCF $7.84 $10.59 $14.88 72
Rev-Margin DCF $5.77 $6.87 $9.22 67

Open the full fair value analysis →

Notify me when SLGL reaches fair value

Put SLGL on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 65/100

Of which business quality 65 · Market factors (momentum, volatility) 51

Profitability 29
Margins and returns on capital today
Quality Growth 94
Are margins and returns improving?
Cashflow 42
Earnings quality: real cash, not paper profit
Fin. Strength 75
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 26
Calm price path (market factor)
Momentum 53
Price trend over the last 3–12 months (market factor)
52W Momentum 78
Distance to the 52-week high (market factor)
Net Issuance 81
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 51/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+68.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+70.9%
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+80.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−344.7% (2020) → −38.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
more than +80 %
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.

SLGL screens 707% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare Sol Gel Technologies Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 647 stocks

Beats the industry median on 1/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 65 · Top 25%
Fair Value upside −87.6% · Bottom 25%
Profitability
Return on assets −23.9% · Below median
Net margin (TTM) −31.6% · Below median
Growth and dividend
Revenue growth −96.6% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 8.31× · Priciest 25%
P/FCF 689.6× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $526.19 $578.81 +10%
Regeneron Pharmaceuticals, Inc REGN $788.04 $1,275 +62%
argenx SE ARGX $959.49 $918.60 −4%
CSL Limited CSL A$176.95 A$194.65 +10%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
BeOne Medicines AG ONC $360.85 $280.94 −22%
Alnylam Pharmaceuticals, Inc ALNY $255.96 $217.88 −15%
Royalty Pharma plc RPRX $58.21 $19.01 −67%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
WuXi Biologics (Cayman) Inc 2269 HK$53.00 HK$58.30 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Sol Gel Technologies Ltd · Fair Value
$8.28 −707%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Sol Gel Technologies Ltd Fair Value". https://www.fairvalue-calculator.com/stock/SLGL

Frequently asked questions

Is Sol Gel Technologies Ltd (SLGL) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of $8.28 versus a price of $66.85, about −88% upside (overvalued).
What is the fair value of SLGL?
Our model-based fair value for Sol Gel Technologies Ltd is $8.28 (as of Sep 27, 2026), built from audited fundamentals. The current price: $66.85.
What is the quality score of SLGL?
Sol Gel Technologies Ltd has a Quality Score of 65/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sol Gel Technologies Ltd (SLGL)?
Our model-based price target is the fair value of $8.28 (as of Sep 27, 2026) from 7 valuation models. Cautious scenario $6.42, optimistic scenario $8.96. It is a calculation from audited fundamentals, not an analyst target.
What is the Sol Gel Technologies Ltd stock forecast for 2026?
Our models put fair value at $8.28, about −88% upside versus a price of $66.85 (overvalued). Cautious scenario $6.42, optimistic scenario $8.96. The calculation is refreshed regularly with new filings.
What growth is priced into Sol Gel Technologies Ltd (SLGL)?
For today's price to be fair in a discounted-cash-flow model, Sol Gel Technologies Ltd would have to grow free cash flow by more than 80 % per year for five years (discount rate 13.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +17.2 % per year. As of Sep 27, 2026.
What discount rate (WACC) does the fair value of SLGL use?
Our models discount Sol Gel Technologies Ltd at 13.2 %: a base by market capitalisation (micro), damped by beta 1.13, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Sol Gel Technologies Ltd that is more than 80 % per year a year over ten years, using the same discount rate (13.2 %) and the same formula as our fair value.
How much growth has Sol Gel Technologies Ltd (SLGL) delivered so far?
Over the past 5 years revenue at Sol Gel Technologies Ltd grew +17.2 % a year. The price currently implies more than 80 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Sol Gel Technologies Ltd (SLGL) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Sol Gel Technologies Ltd (more than 80 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Sol Gel Technologies Ltd (SLGL)?
The free-cash-flow yield on the price is 0.15 %: that much free cash flow Sol Gel Technologies Ltd produces per unit of market value. When it exceeds the discount rate of our models (13.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Sol Gel Technologies Ltd (SLGL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sol Gel Technologies Ltd it is $8.28 per share (as of Sep 27, 2026), against a price of $66.85. It is the blended result of 7 valuation models (cash flow, earnings, asset, dividend).
Is Sol Gel Technologies Ltd stock overvalued or undervalued in 2026?
As of Sep 27, 2026, SLGL trades above its calculated fair value: price $66.85, fair value $8.28, a gap of about −88% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SLGL?
No. The price is what the market pays today ($66.85); the fair value is what the company's own numbers justify ($8.28). For Sol Gel Technologies Ltd the two are $58.57 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sol Gel Technologies Ltd worth?
The market values Sol Gel Technologies Ltd at about $190M (market capitalisation, as of Sep 27, 2026). Per share that is $66.85; our models calculate a fair value of $8.28 per share.
What do the bullish and bearish scenarios say about SLGL?
Our models span a range for Sol Gel Technologies Ltd: cautious scenario $6.42, base $8.28, optimistic $8.96 per share (as of Sep 27, 2026, price $66.85). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Sol Gel Technologies Ltd (SLGL)?
Balance-sheet figures for Sol Gel Technologies Ltd (as of Sep 27, 2026): return on equity −40.9%. They feed the Quality Score of 65/100, which measures business quality independently of the share price.
How far is SLGL from its 52-week high?
Sol Gel Technologies Ltd trades at $66.85, about 32% below its 52-week high of $97.97 and 139% above the low of $27.99 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $8.28 is for.
Which stocks are comparable to Sol Gel Technologies Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sol Gel Technologies Ltd stock attractive at the current price?
The data as of Sep 27, 2026: price $66.85, calculated fair value $8.28 (−88%), Quality Score 65/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SLGL calculated?
We run Sol Gel Technologies Ltd through 7 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $8.28, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 16.1 % above its aggregate fair value. Sol Gel Technologies Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sol Gel Technologies Ltd (SLGL)?
The closing price on Sep 25, 2026 was $66.85. Our model-based fair value is $8.28, about −88% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sol Gel Technologies Ltd right now?
The price sits above even our optimistic bull case ($8.96). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (65/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Sol Gel Technologies Ltd

How large is the market capitalisation of Sol Gel Technologies Ltd (SLGL)?
The market capitalisation of Sol Gel Technologies Ltd is $190M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Sol Gel Technologies Ltd (SLGL)?
Earnings per share at Sol Gel Technologies Ltd are $−5.62. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Sol Gel Technologies Ltd (SLGL)?
The net margin of Sol Gel Technologies Ltd is −31.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sol Gel Technologies Ltd (SLGL)?
The return on equity (ROE) of Sol Gel Technologies Ltd is −40.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sol Gel Technologies Ltd (SLGL)?
On an EBIT basis the return on assets of Sol Gel Technologies Ltd is −30.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sol Gel Technologies Ltd (SLGL)?
The operating margin of Sol Gel Technologies Ltd is −704% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sol Gel Technologies Ltd (SLGL)?
Revenue at Sol Gel Technologies Ltd is growing −96.6% versus a year earlier (3y avg +70.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Sol Gel Technologies Ltd (SLGL)?
Earnings per share at Sol Gel Technologies Ltd are growing +488% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Sol Gel Technologies Ltd (SLGL) hold?
Sol Gel Technologies Ltd holds more cash than debt, $10.0M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Sol Gel Technologies Ltd in the live analysis

One click puts Sol Gel Technologies Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.